What is the difference between Tirzepatide and Retatrutide?

Tirzepatide (CAS 2023788-19-2) is used in dual GIP/GLP-1 incretin receptor research. Retatrutide (CAS 2381247-90-9) is used in triple GIP/GLP-1/glucagon receptor research. The key research differences relate to mechanism of action, receptor selectivity, and experimental endpoints.

Which is better for research — Tirzepatide or Retatrutide?

The choice between Tirzepatide and Retatrutide depends on your research question. Tirzepatide is preferred for studies focused on dual GIP/GLP-1 incretin receptor research. Retatrutide is preferred for triple GIP/GLP-1/glucagon receptor research. Many research programmes study both compounds.

Can Tirzepatide and Retatrutide be used together in research?

Combination studies of Tirzepatide and Retatrutide are an active area of research. Consult published literature for combination protocols relevant to your specific research model.

What purity grade is recommended for Tirzepatide vs Retatrutide research?

Both Tirzepatide and Retatrutide should be sourced at 98%+ purity for reliable research results. Aarise Healthcare supplies both compounds at 98%+ HPLC-verified purity with independent CoA.

Tirzepatide vs Retatrutide — Research Comparison

⚠ Research Use Only: All compounds supplied by Aarise Healthcare are strictly for laboratory research and scientific investigation. Not for human consumption, therapeutic use, or clinical application. Buyers must comply with all applicable local laws and regulations.

A research reference comparing Tirzepatide and Retatrutide — Dual vs triple incretin agonist research comparison. This comparison is for scientific research reference only.

Side-by-Side Comparison

Property	Tirzepatide	Retatrutide
CAS Number	2023788-19-2	2381247-90-9
Category	GLP-1 Agonist	GLP-1 Agonist
Research Use	dual GIP/GLP-1 incretin receptor research	triple GIP/GLP-1/glucagon receptor research
Purity (Aarise)	98%+ HPLC	98%+ HPLC
Form	Lyophilised powder	Lyophilised powder

Research Applications

Tirzepatide is primarily studied for dual GIP/GLP-1 incretin receptor research. Retatrutide is studied for triple GIP/GLP-1/glucagon receptor research. Researchers choose between these compounds based on their specific experimental model and endpoints.

Source Both Compounds from Aarise Healthcare

Aarise Healthcare supplies both Tirzepatide and Retatrutide at 98%+ purity from our WHO-GMP certified facility. Order both compounds together for consistent quality across your comparative research programme.

Request pricing for Tirzepatide and Retatrutide: Contact our research supply team with your quantity requirements. We respond within 24 hours.